Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 21;217(11):e20201181. doi: 10.1084/jem.20201181

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Schmidt et al.

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure S4. — Examples of neutralization of HIV-1 and VSV pseudotyped virus particles by mAbs targeting SARS-CoV-2 S. (A) Images of Huh7.5 cells following infection with rVSVΔG/NG-NanoLuc pseudotyped virus (∼10³ IU/well) in the presence of the indicated concentrations of a human mAb (C144) targeting SARS-CoV-2 S RBD. Images of the entire well of a 96-well plate are shown. (B) Quantification of rVSVΔG/NG-NanoLuc pseudotyped virus infection (measured by flow cytometry (percentage of mNeonGreen-positive cells, green) or by NanoLuc luciferase activity (RLU, blue) in the presence of the indicated concentrations of a human mAb (C102) targeting SARS-CoV-2 S RBD or a control mAb against the Zika virus envelope glycoprotein. Mean and range of two technical replicates are plotted. (C) Quantification of HIV-1_NLΔEnv-NanoLuc or CCNanoLuc/GFP pseudotyped virus infection on the indicated cell lines in the presence of the indicated concentrations of a human mAb (C121) targeting SARS-CoV-2 S RBD infectivity was quantified by measuring NanoLuc luciferase levels (RLU). Mean and range of two technical replicates are plotted.